Archives
-
(S,S)-Nanaomycin A and DNMT3B in NEPC
2026-09-28
Explore how (S,S)-Nanaomycin A can help investigate DNMT3B-driven neuroendocrine prostate cancer. This article translates recent findings on lineage plasticity into practical assay-design and interpretation guidance while distinguishing experimental evidence from clinical promise.
-
Hesperadin: Aurora B Kinase Inhibitor Workflows
2026-09-27
Use Hesperadin to connect Aurora B inhibition with measurable changes in histone H3 phosphorylation, mitotic progression, and cell ploidy. This workflow pairs practical dose-finding and troubleshooting with an important distinction: Aurora B phenotypes can inform checkpoint studies, but they do not directly establish how the Plk1–p31comet pathway disassembles mitotic checkpoint complexes.
-
Trilaurin in Translational Oral Nanomedicine
2026-09-26
Trilaurin (Glycerol Tridodecanoate) offers translational researchers a useful case study in how lipid composition can support oral drug protection, targeted release, and combination therapy. This article connects its material properties to preclinical colon-targeting evidence and practical formulation decisions.
-
Potassium Iodide: Workflows for Thyroid Assays
2026-09-25
Use Potassium Iodide (KI) to build controlled iodide dose-response experiments for thyroid biology and uptake studies—not as an immunotherapy agent. This guide pairs practical solution handling with assay controls and explains how to interpret the product alongside research on responsive tumor-delivery systems.
-
Amiloride (MK-870): A Negative-Control Lens on Entry
2026-09-25
Amiloride (MK-870) is best understood through both its established ion-transport applications and the limits of what its inhibition can show. This article examines a grass carp reovirus study in which amiloride did not block viral entry, showing how negative pharmacology can sharpen cellular endocytosis experiments.
-
Plk1 Regulation of p31comet-Mediated MCC Disassembly
2026-09-24
The study identifies Polo-like kinase 1 (Plk1) as a direct brake on p31comet, showing that Plk1-dependent phosphorylation at S102 suppresses p31comet and TRIP13-mediated disassembly of mitotic checkpoint complexes. This mechanism offers a biochemical explanation for how cells can limit premature checkpoint release while the spindle assembly checkpoint remains active.
-
BI 2536 Workflows for Cancer Drug Response
2026-09-24
Use BI 2536 to probe PLK1-dependent mitosis while separating slowed proliferation from actual cancer-cell killing. A paired assay workflow helps distinguish G2/M accumulation, loss of viability, and apoptosis—responses that a single endpoint can blur.
-
A23187, Free Acid: Read Calcium Perturbation Clearly
2026-09-23
A23187, free acid is a calcium ionophore for studying how calcium perturbation shapes cell responses. This guide shows how to interpret its effects without confusing growth inhibition, cell death, and downstream signaling.
-
Surface-Cleaned BPNSs Rebalance AKI Ferroptosis
2026-09-23
A 2026 Theranostics study shows that hydrogen-reduced, surface-cleaned black phosphorus nanosheets protect injured kidneys by chelating labile iron, limiting ferroptosis, and dampening macrophage-driven inflammation. Its integrated material, biodistribution, transcriptomic, and co-culture design provides a useful framework for studying the ferroptosis–immune axis in acute kidney injury.
-
Leptin (116-130), amide, mouse: Research Workflows
2026-09-22
Leptin (116-130), amide, mouse is a soluble peptide tool for separating leptin-receptor biology from the complexity of full-length hormone preparations. This guide translates its metabolic use cases into reproducible cell-based workflows, pathway-aware controls, and troubleshooting strategies informed by recent inflammasome research.
-
A23187, free acid: Reliable Calcium Assays
2026-09-22
A practical, scenario-driven guide to using A23187, free acid (SKU B6646) in calcium signaling, viability, proliferation, and cytotoxicity workflows. It explains how to separate metabolic viability from cell death, optimize solvent and storage practices, and select a traceable calcium ionophore for reproducible research.
-
Ruxolitinib: From JAK Inhibition to Immune Maps
2026-09-21
Ruxolitinib (INCB018424) is more than a selective JAK1/2 inhibitor: it is a tool for connecting kinase activity with cellular immune states. This article explains how high-dimensional spectral cytometry can improve experimental interpretation across myeloproliferative and tumor-immunology models.
-
Liproxstatin-1 HCl: Ferroptosis Assay Guide
2026-09-21
Liproxstatin-1 HCl provides a selective rescue control for separating ferroptotic lipid damage from apoptosis or hydrogen-peroxide toxicity. This guide translates its nanomolar activity into practical cell-based workflows and shows how the reagent can support acute renal failure and hepatic ischemia/reperfusion injury research.
-
Alda 1: ALDH2 Activator Research Workflows
2026-09-20
Alda 1 provides a practical way to test how ALDH2 activation changes aldehyde handling, cardiomyocyte proliferation, and stress responses. This guide translates recent pressure-overload findings into assay design, optimization steps, and research-use applications spanning cardiac ischemia and radiation-induced dermatitis models.
-
A23187, Free Acid: Measuring Calcium-Driven Cell Death
2026-09-19
A23187, free acid is a calcium ionophore that can reveal how intracellular Ca2+ perturbation translates into growth inhibition, mitochondrial apoptosis, ROS generation, and true cell killing. This guide applies a response-measurement framework from cancer pharmacology to improve assay interpretation and endpoint selection.